Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – IT Business Net
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine…
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…
-
Business22 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business21 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News18 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business18 hours ago1 ASX dividend stock down 43% I’d buy right now